CVS splits the bill

We all know CVS for one thing: receipts long enough to double as winter scarves. Turns out, its corporate structure was getting pretty long as well.

After spending decades assembling a healthcare empire that includes pharmacies, insurance, doctors, and prescription drug middlemen, CVS Health announced that it’s splitting into two publicly traded companies—separating its retail pharmacies from its insurance group and pharmacy benefit manager, Caremark.

The news came alongside a solid earnings report. CVS posted $108.4 billion in quarterly revenue, up 5.4% year-over-year, and raised its full-year profit outlook. But shares tumbled 12.53%, suggesting maybe Wall Street wasn’t ready to celebrate the divorce.

Till debt do us part

CVS wasn’t always America’s healthcare Swiss Army knife. It spent $26.5 billion acquiring Caremark in 2007 and roughly $78 billion on insurer Aetna in 2018 before adding primary-care clinics and home healthcare services. The idea was to make healthcare more efficient by bringing the company that insures you, negotiates your drug prices, and provides your medical care into one union.

But the marriage came with complications. Pharmacy benefit managers, which negotiate drug prices for insurers and employers, have faced growing scrutiny over whether their business practices inflate costs and limit competition. Meanwhile, CVS’s physical pharmacies are dealing with shrinking reimbursement rates, expensive storefronts, and competition from online rivals.

Now CVS plans to spin off its roughly 9,000 retail pharmacies and related businesses by the first half of 2028, leaving Aetna, Caremark, and the rest of its healthcare operations together in what remains. Though CVS hasn’t detailed how it’ll divide its $60.7 billion debt load, both current and long-term debt are expected to retain investment-grade credit ratings.

In good news, CVS isn’t breaking up with your prescriptions. The split won’t send patients to separate locations to pick up medications—although it also doesn’t guarantee lower drug prices or cheaper insurance.

Could the parts be more than the whole?

For Wall Street, that’s the billion-dollar question. Splitting up its care and pharmacy services could help investors see what each business is worth, while giving management more freedom to invest and CVS Pharmacy room to partner with insurers that previously competed with its in-house unit.

But a corporate divorce doesn’t save all. Retail pharmacies will still face pressure on prescription margins, while the insurance and healthcare businesses remain exposed to medical costs and regulatory scrutiny.

The spinoff also doesn’t automatically make either business more profitable. For the millions of Americans navigating insurance claims, prescription prices, and pharmacy visits, the real test isn’t whether two companies are worth more than one: It’s whether either arrangement makes healthcare less of a headache. America’s healthcare system could certainly use a prescription for that.—HC